Emma West

TL;DR: It is shown, in a window-of-opportunity clinical study, that intravenous infusion of oncolytic human Orthoreovirus leads to infection of tumor cells subsequently resected as part of standard clinical care, both in high-grade glioma and in brain metastases, and increases cytotoxic T cell tumor infiltration relative to patients not treated with virus.

TL;DR: It is shown in human patients with colorectal cancer that, after intravenous injection, reovirus can be escorted to the tumor by immune cells, which protect it from neutralizing antibodies in the plasma, and potentially cloud-lifting studies support intravenous administration of reov virus for cancer therapy.

TL;DR: The data suggest that ex vivo freeze-thaw of tumor cells does not effectively mimic in vivo immunogenic necrosis, and advocates careful characterization and optimization of tumor cell-derived vaccine sources for cancer immunotherapy.

TL;DR: How the field of oncolytic virotherapy has developed thus far and what the future may hold are reviewed.

TL;DR: LAKDC pulsed with reovirus represent a novel, clinically practical treatment for ovarian cancer to maximise both direct and innate/adaptive immune‐mediated tumor cell killing.